Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study

PLoS Medicine

Volumn 11, Issue 9, 2014, Pages

  Zipursky, Jonathan ^a   Macdonald, Erin M ^b   Hollands, Simon ^b   Gomes, Tara ^b,c,d,e   Mamdani, Muhammad M ^b,c,d,f,g   Paterson, J Michael ^b,d,h   Lathia, Nina ^e   Juurlink, David N ^a,b,d,i  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g KING SAUD UNIVERSITY   (Saudi Arabia)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SERVICE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; HYPOMAGNESEMIA; LIVER DISEASE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; VERY ELDERLY; CANADA; CASE CONTROL STUDY; CHEMICALLY INDUCED; HEALTH SURVEY; HYPERCALCIURIA; NEPHROCALCINOSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; HYPERCALCIURIA; MALE; NEPHROCALCINOSIS; ONTARIO; POPULATION SURVEILLANCE; PROTON PUMP INHIBITORS; RENAL TUBULAR TRANSPORT, INBORN ERRORS;

EID: 84907952319     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001736     Document Type: Article

References (45)

1. IMS Institute for Healthcare Informatics (2011) The Use of Medicine in the United States: Review of 2010. Available: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf. Accessed 10 April 2014.
2. Richardson P, Hawkey CJ, Stack WA, (1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56: 307–335.
3. Salas M, Ward A, Caro J, (2002) Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2: 17.
4. Poynard T, Lemaire M, Agostini H, (1995) Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7: 661–665.
5. Leonard J, Marshall JK, Moayyedi P, (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047–56; quiz 2057.
6. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, et al. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107: 1011–1019.
7. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN, (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107: 1001–1010.
8. Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, et al. (2012) Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 21: 1155–1172.
9. Blank M-L, Parkin L, Paul C, Herbison P, (2014) A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int doi:10.1038/ki.2014.74
10. Eom C-S, Jeon CY, Lim J-W, Cho E-G, Park SM, et al. (2011) Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183: 310–319.
11. Marcuard SP, Albernaz L, Khazanie PG, (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211–215.
12. Yu EW, Bauer SR, Bain PA, Bauer DC, (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124: 519–526.
13. Famularo G, Gasbarrone L, Minisola G, (2013) Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 1–8.
14. Ma J, Folsom AR, Melnick SL, Eckfeldt JH, Sharrett AR, et al. (1995) Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 48: 927–940.
15. Schimatschek HF, Rempis R, (2001) Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 14: 283–290.
16. Schlingmann KP, Waldegger S, Konrad M, Chubanov V, Gudermann T, (2007) TRPM6 and TRPM7–Gatekeepers of human magnesium metabolism. Biochim Biophys Acta 1772: 813–821.
17. Weisinger JR, Bellorin-Font E, (1998) Magnesium and phosphorus. Lancet 352: 391–396.
18. Epstein M, McGrath S, Law F, (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355: 1834–1836.
19. Arulanantham N, Anderson M, (2011) A 63-year-old man with hypomagnesaemia and seizures. Clin Med (Northfield, Il) 11: 591–593.
20. Broeren M, Geerdink E, (2009) Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern 151: 755–756.
21. Fernandez-Fernandez F, (2010) Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 68: 329–330.
22. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW, (2008) Omeprazole and refractory hypomagnesaemia. BMJ 337: a425.
23. Cundy T, Dissanayake A, (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 69: 338–341.
24. Famularo G, Minisola G, Bravi MC, Colucci P, Gasbarrone L, (2012) Tetany, hypomagnesemia, and proton-pump inhibitors. Am J Med 125: e7–e8.
25. Hoorn EJ, van der Hoek J, de Man R a, Kuipers EJ, Bolwerk C, et al. (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56: 112–116.
26. Mackay JD, Bladon PT, (2010) Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103: 387–395.
27. Hess MW, Hoenderop JGJ, Bindels RJM, Drenth JPH, (2012) Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 36: 405–413.
28. Furlanetto TW, Faulhaber GAM, (2011) Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 171: 1391–1392.
29. Matsuyama J, Tsuji K, Doyama H, Kim F, Takeda Y, et al. (2012) Hypomagnesemia Associated with a Proton Pump Inhibitor. Intern Med 51: 2231–2234.
30. Gandhi NY, Sharif WK, Chadha S, Shakher J, (2012) A patient on long-term proton pump inhibitors develops sudden seizures and encephalopathy: an unusual presentation of hypomagnesaemia. Case Rep Gastrointest Med 2012: 632721.
31. Danziger J, William JH, Scott DJ, Lee J, Lehman L, et al. (2013) Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 83: 692–699.
32. Gau J, Yang Y, (2012) Uses of proton pump inhibitors and hypomagnesemia. … drug Saf 553–559.
33. Koulouridis I, Alfayez M, Tighiouart H, Madias NE, Kent DM, et al. (2013) Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 62: 730–737.
34. Luk CP, Parsons R, Lee YP, Hughes JD, (2013) Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 47: 773–780.
35. Hux JE, Ivis F, Flintoft V, Bica A, (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512–516.
36. Schultz SE, Rothwell DM, Chen Z, Tu K, (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33: 160–166.
37. Juurlink DN, Mhsc TG, Ko DT, Szmitko PE, Austin PC, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718.
38. Juurlink D, Gomes T, Lipsombe L, Austin PC, Hux J, et al. (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339: 1–6.
39. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, et al. (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354: 1352–1361.
40. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, et al. (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154: 854–864.
41. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E, (2010) Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 56: 168–174.
42. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, et al. (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31: 171–174.
43. Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, et al. (2004) Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A 101: 2894–2899.
44. Lainez S, Schlingmann KP, van der Wijst J, Dworniczak B, van Zeeland F, et al. (2013) New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia. Eur J Hum Genet 1–8.
45. Elin RJ, (2010) Assessment of magnesium status for diagnosis and therapy. Magnes Res 23: S194–S1988.